Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Early neuraminidase inhibition shortens hospital length of stay in influenza-infected patients

09 Nov 2018

Early treatment with the neuraminidase inhibitor (NAI) oseltamivir results in shorter length of stay (LOS) in patients hospitalized for influenza, a study has shown.

The retrospective study included 699 patients admitted with influenza, among whom 83.4 percent (n=582) received NAI therapy and only 26.0 percent received the first dose within 6 hours of hospitalization (early group).

Linear and logistic regression analyses showed that NAI was likely to be administered early for patients with diabetes mellitus (p=0.01), pregnancy (p<0.001), fever (p=0.002) or myalgias (p=0.005) at presentation. Immunosuppressed patients were less likely to receive early NAI (p=0.04).

Early NAI was associated with shorter hospital LOS (p<0.001). None of the patients who received early NAI therapy died, whereas 18 deaths occurred among the 399 patients receiving NAI after 6 hours (4.5 percent) and four deaths among the 116 patients not receiving NAI (3.4 percent).

The present data highlight the importance of facilitating earlier therapy in patients with suspected influenza, researchers said, adding that there appears to be a delay in initiating early empiric therapy with NAIs, which has not garnered the same policy attention as early antibacterials for sepsis.

Researchers pointed out a lack of clear guidance to advocate for pre-emptive anti-influenza antivirals for patients with community-acquired pneumonia, despite increasing evidence suggesting viruses, including influenza, are a major cause of pneumonia.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.